ClinicalTrials.gg
CompletedNCT01130168Updated Oct 9, 2015Results posted

The Effects of Antihypertensive Agents on Central Blood Pressure in Healthy Participants and Participants With Hypertension (MK-0000-166) (COMPLETED)

A Phase 1 interventional study of Placebo and Comparator: Amlodipine in Hypertension, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 30 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-10-09.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
38
Allocation
Randomized
Ages
30 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 187 studies testing amlodipine in Hypertension — 6 open to participants now, 8 under way, 2 of them phase 3. Amlodipine · Hypertension.

Enrollment
159th of 186
38 · median 180
Started
2010
with 11 others
Phase 1
17 of 187
none open now
Registered
93rd of 187
by date
Lead sponsor
3 of 187
Merck Sharp & Dohme LLC

Among the 187 studies testing amlodipine in Hypertension, this one is the 159th largest by enrollment of the 186 interventional ones that give a count, is one of 12 that started in 2010, is one of 17 in phase 1, and was the 93rd registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 911 are open to participants now.

Browse Hypertension studies →

Open to participants now

6 of the 187 studies testing amlodipine in Hypertension are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About amlodipine

Amlodipine: first FDA approval 1992 (NORVASC), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 556 Hypertension studies recruiting now, 262 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 137 take healthy volunteers.

This study: 30 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 187 studies testing amlodipine in Hypertension, or all of them as a file.
02

Study summary

This study will test the relationship between CBP (central blood pressure) and PBP (peripheral blood pressure) effects after single and multiple doses of Isosorbide mononitrate extended release (ISMN ER) or Amlodipine besylate in participants with hypertension.

03

Conditions studied

  • Hypertension

Browse trials for

04

Who can participate

Ages eligible
30 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant is a male or female between 30 and 65 years of age (inclusive) at the pre-study (screening)
  • Female participant of must have a negative pregnancy test
  • Participant has a brachial systolic blood pressure >130 mm Hg

and \<180 mm Hg

  • Participant has a (BMI) that is >20 kg/m\^2 and \<35 kg/m\^2
  • Participant has been a nonsmoker and/or has not used nicotine or nicotine-containing products for at least approximately 6 months

Exclusion criteria

Exclusion Criteria:

  • Female Participant is pregnant or lactating
  • Participant anticipates the use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) other than acetaminophen
  • Participant is currently a user (including "recreational use") of any illicit drugs, has a history of drug or alcohol abuse within approximately 2 years, or has a positive prestudy urine drug screen
  • Participant has a condition for which there is a warning, , or precaution against the use of ISMN ER including: acute myocardial infarction or congestive heart failure, hypotension, volume depletion, and pregnancy
  • Participant has a history of significant drug allergy or any adverse experience of a serious nature related to the administration of either a marketed or an drug, including nitrates, nitrites, Amlodipine, and ISMN ER
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
38 participants (actual)

Study arms

  • Experimental
    Placebo/ISMN ER/Amlodipine (Sequence 1)

    Participants received a dose-matched Placebo capsule orally for 4 weeks during Period 1, followed by a ISMN ER 30 mg capsule orally for 4 weeks during Period 2, followed by Amlodipine 10 mg (two 5 mg capsules) orally for 4 weeks during Period 3, with a 2-week washout between each period.

    Drug: Placebo · Drug: Comparator: Amlodipine · Drug: Comparator: ISMN ER

  • Experimental
    ISMN ER/Amlodipine/Placebo (Sequence 2)

    Participants received a ISMN ER 30 mg capsule orally for 4 weeks during Period 1, followed by Amlodipine 10 mg (two 5 mg capsules) orally for 4 weeks during Period 2, followed by a dose-matched Placebo capsule orally for 4 weeks during Period 3, with a 2-week washout between each period.

    Drug: Placebo · Drug: Comparator: Amlodipine · Drug: Comparator: ISMN ER

  • Experimental
    Amlodipine/Placebo/ISMN ER (Sequence 3)

    Participants received Amlodipine 10 mg (two 5 mg capsules) orally for 4 weeks during Period 1, followed by a dose-matched Placebo capsule orally for 4 weeks during Period 2, followed by a ISMN ER 30 mg capsule orally for 4 weeks during Period 3, with a 2-week washout between each period.

    Drug: Placebo · Drug: Comparator: Amlodipine · Drug: Comparator: ISMN ER

  • Experimental
    ISMN ER/Placebo/Amlodipine (Sequence 4)

    Participants received a ISMN ER 30 mg capsule orally for 4 weeks during Period 1, followed by a dose-matched Placebo capsule orally for 4 weeks during Period 2, followed by Amlodipine 10 mg (two 5 mg capsules) orally for 4 weeks during Period 3, with a 2-week washout between each period.

    Drug: Placebo · Drug: Comparator: Amlodipine · Drug: Comparator: ISMN ER

  • Experimental
    Placebo/Amlodipine/ISMN ER (Sequence 5)

    Participants received a dose-matched Placebo capsule orally for 4 weeks during Period 1, followed by Amlodipine 10 mg (two 5 mg capsules) orally for 4 weeks during Period 2, followed by a ISMN ER 30 mg capsule orally for 4 weeks during Period 3, with a 2-week washout between each period.

    Drug: Placebo · Drug: Comparator: Amlodipine · Drug: Comparator: ISMN ER

  • Experimental
    Amlodipine/ISMN ER/Placebo (Sequence 6)

    Participants received Amlodipine 10 mg (two 5 mg capsules) orally for 4 weeks during Period 1, followed by a ISMN ER 30 mg capsule orally for 4 weeks during Period 2, followed by a dose-matched Placebo capsule for 4 weeks during Period, with a 2-week washout between each period.

    Drug: Placebo · Drug: Comparator: Amlodipine · Drug: Comparator: ISMN ER

Interventions

06

What researchers measure

Primary outcomes

  1. Time-weighted Average (TWA) Change From Baseline (0 Hours) to 12 Hours in Heart-Rate-Corrected Augmentation Index (AIx) After A Single Dose of Treatment

    The augmentation index (AIx) is a measure of systemic arterial stiffness, and is the ratio of augmented aortic pressure (Δ P) to central pulse pressure expressed as a percent. AIx = (ΔP/PP) x 100, where P = pressure and PP = Pulse Pressure. Single dose effects on AIx were estimated as a time-weighted average change from baseline over the 12-hour post single dose observation period. Because heart rate (HR) affects AIx, AIx was corrected to a HR of 75 beats per minute (bpm) as follows: HR-corrected AIx = -0.39 x (75 - HR) + AIx. This value was used for all AIx analyses.

    Time frame: Baseline (0 hrs), 12 hours post-dose (Day 1)

  2. Change From Baseline (0 Hours) to Week 4 in Heart-Rate-Corrected AIx After Multiple Doses of Treatment

    The augmentation index (AIx) is a measure of systemic arterial stiffness, and is the ratio of augmented aortic pressure (Δ P) to central pulse pressure expressed as a percent. AIx = (ΔP/PP) x 100, where P = pressure and PP = Pulse Pressure. Because heart rate (HR) affects AIx, AIx was corrected to a HR of 75 beats per minute (bpm) as follows: HR-corrected AIx = -0.39 x (75 - HR) + AIx. This value was used for all AIx analyses.

    Time frame: Baseline (0 hrs), 24 hours after the Day 28 dose

  3. TWA Change From Baseline (0 Hours) to 12 Hours in Central Systolic Blood Pressure (SBP) After A Single Dose of Treatment

    Central SBP was measured by the SphygmoCor® device. Single dose effects on central SBP were estimated as a time-weighted average change from baseline over the 12-hour post single dose observation period.

    Time frame: Baseline (0 hrs), 12 hours post-dose (Day 1)

  4. Change From Baseline (0 Hours) to Week 4 in Central SBP After Multiple Doses of Treatment

    Central SBP was measured by the SphygmoCor® device. Central SBP was measured at baseline and at 24 hours post dose on Day 28 (Week 4) and expressed as a change from baseline.

    Time frame: Baseline (0 hrs), 24 hours after the Day 28 dose

  5. TWA Change From Baseline (0 Hours) to 12 Hours in Central Diastolic Blood Pressure (DBP) After A Single Dose of Treatment

    Central DBP was measured by the SphygmoCor® device. Single dose effects on central DBP were estimated as a time-weighted average change from baseline over the 12-hour post single dose observation period.

    Time frame: Baseline (0 hrs), 12 hours post-dose (Day 1)

  6. Change From Baseline (0 Hours) to Week 4 in Central DBP After Multiple Doses of Treatment

    Central DBP was measured by the SphygmoCor® device. Central DBP was measured at baseline and at 24 hours post dose on Day 28 (Week 4) and expressed as a change from baseline.

    Time frame: Baseline (0 hrs), 24 hours after the Day 28 dose

  7. TWA Change From Baseline (0 Hours) to 12 Hours in Peripheral SBP After A Single Dose of Treatment

    Peripheral SBP was measured by Brachial Sphygmomanometer (standard cuff). Single dose effects on peripheral SBP were estimated as a time-weighted average change from baseline over the 12-hour post single dose observation period.

    Time frame: Baseline (0 hrs), 12 hours post-dose (Day 1)

  8. Change From Baseline (0 Hours) to Week 4 in Peripheral SBP After Multiple Doses of Treatment

    Peripheral SBP was measured by Brachial Sphygmomanometer (standard cuff). Peripheral SBP was measured at baseline and at 24 hours post dose on Day 28 (Week 4) and expressed as a change from baseline.

    Time frame: Baseline (0 hrs), 24 hours after the Day 28 dose

  9. TWA Change From Baseline (0 Hours) to 12 Hours in Peripheral DBP After A Single Dose of Treatment

    Peripheral DBP was measured by Brachial Sphygmomanometer (standard cuff). Single dose effects on peripheral DBP were estimated as a time-weighted average change from baseline over the 12-hour post single dose observation period.

    Time frame: Baseline (0 hrs), 12 hours post-dose (Day 1)

  10. Change From Baseline (0 Hours) to Week 4 in Peripheral DBP After Multiple Doses of Treatment

    Peripheral SBP was measured by Brachial Sphygmomanometer (standard cuff). Peripheral DBP was measured at baseline and at 24 hours post dose on Day 28 (Week 4) and expressed as a change from baseline.

    Time frame: Baseline (0 hrs), 24 hours after the Day 28 dose

07

Results

Posted May 28, 2012

Participant flow

Period 1
Participant flow — Period 1
MilestonePlacebo/ISMN ER/Amlodipine (Sequence 1)ISMN ER/Amlodipine/Placebo (Sequence 2)Amlodipine/Placebo/ISMN ER (Sequence 3)ISMN ER/Placebo/Amlodipine (Sequence 4)Placebo/Amlodipine/ISMN ER (Sequence 5)Amlodipine/ISMN ER/Placebo (Sequence 6)
Started676856
Completed665556
Not completed011300
Withdrew: Withdrawal by subject010100
Withdrew: Discontinued for other reason001100
Withdrew: Adverse event000100
Period 2
Participant flow — Period 2
MilestonePlacebo/ISMN ER/Amlodipine (Sequence 1)ISMN ER/Amlodipine/Placebo (Sequence 2)Amlodipine/Placebo/ISMN ER (Sequence 3)ISMN ER/Placebo/Amlodipine (Sequence 4)Placebo/Amlodipine/ISMN ER (Sequence 5)Amlodipine/ISMN ER/Placebo (Sequence 6)
Started665556
Completed665556
Not completed000000
Period 3
Participant flow — Period 3
MilestonePlacebo/ISMN ER/Amlodipine (Sequence 1)ISMN ER/Amlodipine/Placebo (Sequence 2)Amlodipine/Placebo/ISMN ER (Sequence 3)ISMN ER/Placebo/Amlodipine (Sequence 4)Placebo/Amlodipine/ISMN ER (Sequence 5)Amlodipine/ISMN ER/Placebo (Sequence 6)
Started665556
Completed665556
Not completed000000

Outcome measures

PrimaryTime-weighted Average (TWA) Change From Baseline (0 Hours) to 12 Hours in Heart-Rate-Corrected Augmentation Index (AIx) After A Single Dose of Treatment

The augmentation index (AIx) is a measure of systemic arterial stiffness, and is the ratio of augmented aortic pressure (Δ P) to central pulse pressure expressed as a percent. AIx = (ΔP/PP) x 100, where P = pressure and PP = Pulse Pressure. Single dose effects on AIx were estimated as a time-weighted average change from baseline over the 12-hour post single dose observation period. Because heart rate (HR) affects AIx, AIx was corrected to a HR of 75 beats per minute (bpm) as follows: HR-corrected AIx = -0.39 x (75 - HR) + AIx. This value was used for all AIx analyses.

Time frame:
Baseline (0 hrs), 12 hours post-dose (Day 1)
Reported as:
Least squares mean · percent
Time-weighted Average (TWA) Change From Baseline (0 Hours) to 12 Hours in Heart-Rate-Corrected Augmentation Index (AIx) After A Single Dose of Treatment
percentISMN ERAmlodipinePlacebo
Time-weighted Average (TWA) Change From Baseline (0 Hours) to 12 Hours in Heart-Rate-Corrected Augmentation Index (AIx) After A Single Dose of Treatment-11.1 ± 4.5-0.7 ± 4.52.1 ± 4.5
Statistical analysis
  • ISMN ER vs Placebo · ANOVA · p = <0.0005 · Mean difference (final values): -13.1 · 95% CI -15.3 to -10.9
  • Amlodipine vs Placebo · ANOVA · p = 0.016 · Mean difference (final values): -2.7 · 95% CI -4.9 to -0.6
PrimaryChange From Baseline (0 Hours) to Week 4 in Heart-Rate-Corrected AIx After Multiple Doses of Treatment

The augmentation index (AIx) is a measure of systemic arterial stiffness, and is the ratio of augmented aortic pressure (Δ P) to central pulse pressure expressed as a percent. AIx = (ΔP/PP) x 100, where P = pressure and PP = Pulse Pressure. Because heart rate (HR) affects AIx, AIx was corrected to a HR of 75 beats per minute (bpm) as follows: HR-corrected AIx = -0.39 x (75 - HR) + AIx. This value was used for all AIx analyses.

Time frame:
Baseline (0 hrs), 24 hours after the Day 28 dose
Reported as:
Least squares mean · percent
Change From Baseline (0 Hours) to Week 4 in Heart-Rate-Corrected AIx After Multiple Doses of Treatment
percentISMN ERAmlodipinePlacebo
Change From Baseline (0 Hours) to Week 4 in Heart-Rate-Corrected AIx After Multiple Doses of Treatment2.5 ± 6.2-4.7 ± 6.21.2 ± 6.2
Statistical analysis
  • ISMN ER vs Placebo · ANOVA · p = 0.407 · Mean difference (final values): 1.3 · 95% CI -1.7 to 4.3
  • Amlodipine vs Placebo · ANOVA · p = <0.0005 · Mean difference (final values): -5.9 · 95% CI -8.9 to -2.9
PrimaryTWA Change From Baseline (0 Hours) to 12 Hours in Central Systolic Blood Pressure (SBP) After A Single Dose of Treatment

Central SBP was measured by the SphygmoCor® device. Single dose effects on central SBP were estimated as a time-weighted average change from baseline over the 12-hour post single dose observation period.

Time frame:
Baseline (0 hrs), 12 hours post-dose (Day 1)
Reported as:
Least squares mean · mm mercury (Hg)
TWA Change From Baseline (0 Hours) to 12 Hours in Central Systolic Blood Pressure (SBP) After A Single Dose of Treatment
mm mercury (Hg)ISMN ERAmlodipinePlacebo
TWA Change From Baseline (0 Hours) to 12 Hours in Central Systolic Blood Pressure (SBP) After A Single Dose of Treatment-14.7 ± 7.7-3.6 ± 7.72.7 ± 7.7
Statistical analysis
  • ISMN ER vs Placebo · ANOVA · p = <0.0005 · Mean difference (final values): -17.4 · 95% CI -21.2 to -10.1
  • Amlodipine vs Placebo · ANOVA · p = 0.001 · Mean difference (final values): -6.3 · 95% CI -17.4 to -6.3
PrimaryChange From Baseline (0 Hours) to Week 4 in Central SBP After Multiple Doses of Treatment

Central SBP was measured by the SphygmoCor® device. Central SBP was measured at baseline and at 24 hours post dose on Day 28 (Week 4) and expressed as a change from baseline.

Time frame:
Baseline (0 hrs), 24 hours after the Day 28 dose
Reported as:
Least squares mean · mm mercury (Hg)
Change From Baseline (0 Hours) to Week 4 in Central SBP After Multiple Doses of Treatment
mm mercury (Hg)ISMN ERAmlodipinePlacebo
Change From Baseline (0 Hours) to Week 4 in Central SBP After Multiple Doses of Treatment-0.7 ± 11.6-12.9 ± 11.63.2 ± 11.6
Statistical analysis
  • ISMN ER vs Placebo · ANOVA · p = 0.186 · Mean difference (final values): -3.8 · 95% CI -9.5 to 1.8
  • Amlodipine vs Placebo · ANOVA · p = <0.0005 · Mean difference (final values): -16.1 · 95% CI -21.7 to -10.5
PrimaryTWA Change From Baseline (0 Hours) to 12 Hours in Central Diastolic Blood Pressure (DBP) After A Single Dose of Treatment

Central DBP was measured by the SphygmoCor® device. Single dose effects on central DBP were estimated as a time-weighted average change from baseline over the 12-hour post single dose observation period.

Time frame:
Baseline (0 hrs), 12 hours post-dose (Day 1)
Reported as:
Least squares mean · mm mercury (Hg)
TWA Change From Baseline (0 Hours) to 12 Hours in Central Diastolic Blood Pressure (DBP) After A Single Dose of Treatment
mm mercury (Hg)ISMN ERAmlodipinePlacebo
TWA Change From Baseline (0 Hours) to 12 Hours in Central Diastolic Blood Pressure (DBP) After A Single Dose of Treatment-8.2 ± 5.9-2.1 ± 5.91.1 ± 5.9
Statistical analysis
  • ISMN ER vs Placebo · ANOVA · p = <0.0005 · Median difference (final values): -9.2 · 95% CI -12.1 to -6.4
  • Amlodipine vs Placebo · ANOVA · p = 0.035 · Mean difference (final values): -3.5 · 95% CI -6.0 to -0.3
PrimaryChange From Baseline (0 Hours) to Week 4 in Central DBP After Multiple Doses of Treatment

Central DBP was measured by the SphygmoCor® device. Central DBP was measured at baseline and at 24 hours post dose on Day 28 (Week 4) and expressed as a change from baseline.

Time frame:
Baseline (0 hrs), 24 hours after the Day 28 dose
Reported as:
Least squares mean · mm mercury (Hg)
Change From Baseline (0 Hours) to Week 4 in Central DBP After Multiple Doses of Treatment
mm mercury (Hg)ISMN ERAmlodipinePlacebo
Change From Baseline (0 Hours) to Week 4 in Central DBP After Multiple Doses of Treatment-0.7 ± 9.0-7.7 ± 9.01.1 ± 9.0
Statistical analysis
  • ISMN ER vs Placebo · ANOVA · p = 0.428 · Mean difference (final values): -1.8 · 95% CI -6.1 to 2.6
  • Amlodipine vs Placebo · ANOVA · p = <0.0005 · Mean difference (final values): -8.8 · 95% CI -13.1 to -4.5
PrimaryTWA Change From Baseline (0 Hours) to 12 Hours in Peripheral SBP After A Single Dose of Treatment

Peripheral SBP was measured by Brachial Sphygmomanometer (standard cuff). Single dose effects on peripheral SBP were estimated as a time-weighted average change from baseline over the 12-hour post single dose observation period.

Time frame:
Baseline (0 hrs), 12 hours post-dose (Day 1)
Reported as:
Least squares mean · mm mercury (Hg)
TWA Change From Baseline (0 Hours) to 12 Hours in Peripheral SBP After A Single Dose of Treatment
mm mercury (Hg)ISMN ERAmlodipinePlacebo
TWA Change From Baseline (0 Hours) to 12 Hours in Peripheral SBP After A Single Dose of Treatment-12.1 ± 7.7-3.1 ± 7.71.7 ± 7.7
Statistical analysis
  • ISMN ER vs Placebo · ANOVA · p = <0.0005 · Mean difference (final values): -13.7 · 95% CI -17.5 to -10.0
  • Amlodipine vs Placebo · ANOVA · p = 0.015 · Mean difference (final values): -4.8 · 95% CI -8.5 to -1.0
PrimaryChange From Baseline (0 Hours) to Week 4 in Peripheral SBP After Multiple Doses of Treatment

Peripheral SBP was measured by Brachial Sphygmomanometer (standard cuff). Peripheral SBP was measured at baseline and at 24 hours post dose on Day 28 (Week 4) and expressed as a change from baseline.

Time frame:
Baseline (0 hrs), 24 hours after the Day 28 dose
Reported as:
Least squares mean · mm mercury (Hg)
Change From Baseline (0 Hours) to Week 4 in Peripheral SBP After Multiple Doses of Treatment
mm mercury (Hg)ISMN ERAmlodipinePlacebo
Change From Baseline (0 Hours) to Week 4 in Peripheral SBP After Multiple Doses of Treatment-0.6 ± 11.2-11.4 ± 11.23.9 ± 11.2
Statistical analysis
  • ISMN ER vs Placebo · ANOVA · p = 0.112 · Mean difference (final values): -4.4 · 95% CI -9.9 to 1.0
  • Amlodipine vs Placebo · ANOVA · p = <0.0005 · Mean difference (final values): -15.3 · 95% CI -20.7 to -9.8
PrimaryTWA Change From Baseline (0 Hours) to 12 Hours in Peripheral DBP After A Single Dose of Treatment

Peripheral DBP was measured by Brachial Sphygmomanometer (standard cuff). Single dose effects on peripheral DBP were estimated as a time-weighted average change from baseline over the 12-hour post single dose observation period.

Time frame:
Baseline (0 hrs), 12 hours post-dose (Day 1)
Reported as:
Least squares mean · mm mercury (Hg)
TWA Change From Baseline (0 Hours) to 12 Hours in Peripheral DBP After A Single Dose of Treatment
mm mercury (Hg)ISMN ERAmlodipinePlacebo
TWA Change From Baseline (0 Hours) to 12 Hours in Peripheral DBP After A Single Dose of Treatment-8.0 ± 5.7-2.0 ± 5.71.0 ± 5.7
Statistical analysis
  • ISMN ER vs Placebo · ANOVA · p = <0.0005 · Mean difference (final values): -9.0 · 95% CI -11.8 to -6.2
  • Amlodipine vs Placebo · ANOVA · p = 0.039 · Mean difference (final values): -3.0 · 95% CI -5.8 to -0.2
PrimaryChange From Baseline (0 Hours) to Week 4 in Peripheral DBP After Multiple Doses of Treatment

Peripheral SBP was measured by Brachial Sphygmomanometer (standard cuff). Peripheral DBP was measured at baseline and at 24 hours post dose on Day 28 (Week 4) and expressed as a change from baseline.

Time frame:
Baseline (0 hrs), 24 hours after the Day 28 dose
Reported as:
Least squares mean · mm mercury (Hg)
Change From Baseline (0 Hours) to Week 4 in Peripheral DBP After Multiple Doses of Treatment
mm mercury (Hg)ISMN ERAmlodipinePlacebo
Change From Baseline (0 Hours) to Week 4 in Peripheral DBP After Multiple Doses of Treatment-1.4 ± 8.7-7.5 ± 8.71.0 ± 8.7
Statistical analysis
  • ISMN ER vs Placebo · ANOVA · p = 0.267 · Mean difference (final values): -2.4 · 95% CI -6.6 to 1.8
  • Amlodipine vs Placebo · ANOVA · p = <0.0005 · Mean difference (final values): -8.5 · 95% CI -12.7 to -4.3

Adverse events

Non-serious events are listed at a 5.0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—0/34 (0%)7/34 (20.6%)
ISMN ER—0/38 (0%)18/38 (47.4%)
Amlodipine—0/37 (0%)9/37 (24.3%)
Most frequent other events
Most frequent other events
EventPlaceboISMN ERAmlodipine
HeadacheNervous system disorders6/3416/386/37
Tension HeadacheNervous system disorders2/341/380/37
NauseaGastrointestinal disorders0/342/382/37
VomitingGastrointestinal disorders1/341/382/37
Oedema PeripheralGeneral disorders0/340/382/37

Baseline characteristics

Age, Continuous
Age, Continuous(years)All Participants
Mean49 ± 7.05
Sex: Female, Male
Sex: Female, Male(Participants)All Participants
Female11
Male22
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2010, a primary completion of Nov 2010 and a completion of Nov 2010. It does not say whether these dates are actual or estimated.

Results were first posted in May 2012, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2010
First posted
May 25, 2010
Start
May 2010
Primary completionActual
Nov 2010
CompletionActual
Nov 2010
Results first posted
May 28, 2012
Last update
Oct 9, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 9, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01130168
Responsible party
Sponsor
First posted
May 25, 2010
Start date
May 2010
Primary completion
Nov 2010
Completion
Nov 2010
Results posted
May 28, 2012
Last update
Oct 9, 2015

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Amlodipine · Isosorbide mononitrate

Start the discussion